Recovery Blueprint: Mifepristone Access and the Jurisprudential Standing Gap

The Structural Problem

The Supreme Court's decision to maintain mifepristone's availability via telehealth represents not a resolution but a temporary containment of a deeper architectural failure. The case revealed that standing doctrine—the constitutional requirement that plaintiffs demonstrate concrete injury before accessing federal courts—has become sufficiently elastic that medical professionals opposed to abortion can credibly claim injury from the mere existence of another provider's prescribing practices, even when they are not required to participate.

The symptom is visible: years of litigation over an FDA-approved medication with a twenty-year safety record, culminating in district court orders that would have restricted access nationwide based on speculative harm. But the root cause is structural: Article III's "case or controversy" requirement has no enforcement mechanism adequate to prevent determined ideological plaintiffs from manufacturing standing through increasingly creative theories of third-party harm, psychological distress, or conscience burden.

The current design is insufficient because it places the burden of dismissal on overworked district courts and requires appellate correction after nationwide injunctions have already issued. By the time the Supreme Court corrects a standing defect, the litigation has already achieved its disruptive effect—uncertainty in the pharmaceutical supply chain, chilling effects on prescriber behavior, and years of legal costs imposed on the FDA and medication manufacturers.

Root Cause: The Standing Doctrine's Enforcement Gap

The structural gap is not in the doctrine itself but in its ex post enforcement model. Standing is currently assessed at the pleading stage by the trial judge, with correction available only through appeal. This creates three cascading failures:

First, no pre-filing screening mechanism prevents facially deficient claims from entering the system. Unlike securities fraud or prisoner litigation, which face heightened pleading standards and mandatory screening, challenges to agency regulatory decisions face only the general Rule 12(b)(1) standard.

Second, no penalty structure deters serial re-litigation of standing theories. A plaintiff whose first theory fails can return with a revised complaint asserting new injuries. The Alliance for Hippocratic Medicine's litigation strategy demonstrated this: when direct harm theories proved weak, plaintiffs pivoted to associational standing and third-party complications.

Third, nationwide injunctions allow a single district court's standing error to bind the entire pharmaceutical system before appellate review. The structural incentive is clear: forum shop for a sympathetic district, assert creative standing theories, and secure a nationwide remedy before the appellate process can correct the jurisdictional defect.

The machine is designed to optimize for access to courts, a worthy principle. But it has no circuit breaker for when that access is weaponized to impose nationwide regulatory paralysis through threshold procedural claims.

Calibration One: Amend 28 U.S.C. § 1331 to Require Pre-Filing Certification in Regulatory Review Cases

Congress should amend the general federal question jurisdiction statute to require pre-filing certification for challenges to FDA drug approvals or REMS modifications. The amendment would require plaintiffs to submit a standing declaration to the court before filing, identifying with specificity: (1) the injury in fact; (2) the causal link to the challenged agency action; and (3) the likelihood that the requested relief would redress the injury.

The court would have 14 days to review the certification. If the standing theory relies on third-party conduct, psychological harm, or conscience objections to others' legal activities, the case would be assigned to a magistrate judge for an immediate evidentiary hearing on injury-in-fact. No injunctive relief could issue until standing is affirmatively established on the record.

Implementation authority: Congress, through amendment to Title 28.

Structural repair: This eliminates the asymmetric warfare advantage. Plaintiffs can no longer impose discovery costs, expert witness burdens, and regulatory uncertainty while the threshold question of their right to sue remains unresolved. The current system back-loads the standing inquiry; this front-loads it, matching the high stakes of nationwide pharmaceutical regulation.

Calibration Two: Codify the Zone-of-Interests Test for APA Claims Against FDA Drug Approvals

Congress should amend the Administrative Procedure Act, 5 U.S.C. § 702, to provide that judicial review of FDA drug approvals and risk mitigation strategies is available only to plaintiffs who fall within the zone of interests protected by the Federal Food, Drug, and Cosmetic Act. The amendment would specify that physicians, medical associations, and third parties asserting conscience-based or ideological objections to a medication's existence are outside that zone unless they can demonstrate a particularized competitive or professional injury distinct from their disagreement with the agency's policy judgment.

This would codify the prudential limitation that currently exists in doctrine but is inconsistently applied. The zone-of-interests test asks: Is this plaintiff the kind of person Congress intended to protect when it created this cause of action? For the FDCA, that zone includes patients, manufacturers with competitive interests, and providers with direct regulatory burdens—not ideological opponents of legal medical procedures.

Implementation authority: Congress, through amendment to the APA.

Structural repair: This prevents standing-by-objection. The current gap allows plaintiffs to transform their moral opposition to abortion into a judicially cognizable injury by claiming stress, conscience burden, or hypothetical future emergency room encounters. Closing the zone-of-interests gap ensures that the courts adjudicate regulatory compliance, not culture war referenda.

Calibration Three: Mandate Single-District Scope for Preliminary Injunctions in Cases Where Standing Remains Contested

If the first two calibrations prove legislatively unattainable, the federal courts can self-impose a procedural rule: when a preliminary injunction is sought in a case where the defendant has filed a motion to dismiss for lack of standing, the scope of any injunction must be limited to the parties and the judicial district unless and until standing is definitively established on appeal.

This would not require statutory amendment. The Supreme Court or the Judicial Conference could adopt it as a rule of judicial administration under the All Writs Act, 28 U.S.C. § 1651. It operationalizes the principle that extraordinary relief should not extend beyond the court's confidently established jurisdiction.

Implementation authority: Supreme Court or Judicial Conference, through rule-making.

Structural repair: This decouples the preliminary injunction from the nationwide scope while the threshold question remains live. A district court's error on standing no longer paralyzes the national pharmaceutical system. The plaintiff can still obtain relief if they ultimately prevail on standing, but the relief scales with the certainty of jurisdiction.

Near-Term Feasibility

Calibration Three is the most achievable. It requires no legislative action and operates within the judiciary's inherent authority to manage its own remedial processes. Calibration Two is harder but still plausible in a Congress motivated by pharmaceutical access or regulatory stability concerns. Calibration One, while the most structurally robust, would face objections as a constraint on access to courts.

The minimum necessary repair is Calibration Three. Without it, the mifepristone litigation pattern becomes a template: identify a politically controversial medication, assert creative standing theories, forum shop, and secure a nationwide injunction that forces settlement or appellate correction years later. The system cannot sustain that cycle. The standing doctrine must have an enforcement mechanism that matches its constitutional importance, or it ceases to be a doctrine at all—and becomes merely a pleading hurdle that well-resourced ideological plaintiffs can engineer their way past.